Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
news icon
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
news icon
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
corporate icon
Polysorbate Analysis
CTech™ SoloVPE System enables the PS80 and PS20 stock solution to be measured without dilution and highly reproducible results through variable pathlength technology.
external link icon
Repligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. 2014 Revenue Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December 31, 2014. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic
external link icon
Repligen to Present at Stifel Healthcare Conference 2014
WALTHAM, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19 at 10:55 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. The Repligen presentation will be webcast live and will be accessible through the Investor Events section of Company's website. The webcast and slide presentation will also be archived on the Company's website for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
external link icon
Repligen Receives Complete Response Letter from FDA for RG1068 NDA
Repligen Corporation (NASDAQ:RGEN) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for RG1068 (synthetic human secretin). RG1068 was evaluated in a Phase 3 study to improve detection of pancreatic duct abnormalities in combination with MRI in patients with known or suspected pancreatitis. The CRL indicates that the FDA has completed its review of the RG1068 NDA and has determined that additional clinical efficacy and safety trial data will be required to support potential approval of the NDA. There were no specific safety concerns cited in the CRL, although safety will continue to be monitored in conjunction with any future clinical trial. No deficiencies were cited in the CRL with respect to the manufacturing, pharmacology or toxicology sections of the NDA. “We will continue to engage in dialogue with the FDA to determine the design and scope of a clinical
external link icon
Repligen to Present at Cowen and Company Health Care Conference
external link icon
Repligen to Present at the William Blair 2018 Growth Stock Conference
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Tony J. Hunt, Chief Executive Officer, will present at the William Blair 2018 Growth Stock Conference. The conference will take place on June 12-14 in Chicago, and the Repligen presentation is scheduled for Wednesday, June 13 at 11:20 a.m. CT.

A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Present at Baird’s 2017 Global Healthcare Conference
WALTHAM, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Baird’s 2017 Healthcare Conference in New York on Wednesday, September 6, at 9:05 a.m. EDT. A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (including XCell™ ATF systems,
external link icon
Repligen to Present at Baird Global Healthcare Conference 2016
WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at Baird’s annual Global Healthcare Conference being held September 7-8, 2016 in New York.  The Repligen presentation will take place at 8:30 a.m. on Thursday, September 8th.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development